

# A global phase III randomized controlled trial of etanercept and effect of dose reduction

British Journal of Dermatology

152, 1304-1312

DOI: [10.1111/j.1365-2133.2005.06688.x](https://doi.org/10.1111/j.1365-2133.2005.06688.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. British Journal of Dermatology, 2005, 153, 486-497.	1.4	245
2	Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. British Journal of Dermatology, 2005, 153, 1192-1199.	1.4	125
4	Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches. Journal of Cutaneous Medicine and Surgery, 2005, 9, 18-25.	0.6	13
7	Prise en charge thérapeutique du psoriasis en plaques : apport des anti-TNF $\alpha$ . Annales De Dermatologie Et De Venereologie, 2005, 132, 6-9.	0.5	0
8	The treatment of psoriasis with etanercept. Seminars in Cutaneous Medicine and Surgery, 2005, 24, 28-36.	1.6	6
9	Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet, The, 2006, 367, 29-35.	6.3	979
10	Biological therapy for psoriasis: infliximab, etanercept, adalimumab, efalizumab and alefacept. Expert Review of Dermatology, 2006, 1, 207-216.	0.3	3
11	Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. Journal of Dermatological Treatment, 2006, 17, 9-17.	1.1	118
12	Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database. Journal of the American Academy of Dermatology, 2006, 54, S92-S100.	0.6	68
13	Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. Journal of the American Academy of Dermatology, 2006, 54, S101-S111.	0.6	98
14	Etanercept for the treatment of psoriasis in the elderly. Journal of the American Academy of Dermatology, 2006, 55, 517-519.	0.6	53
15	Histopathologic findings in primary erythromelalgia are nonspecific: Special studies show a decrease in small nerve fiber density. Journal of the American Academy of Dermatology, 2006, 55, 519-522.	0.6	59
16	Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. Journal of the American Academy of Dermatology, 2006, 55, 598-606.	0.6	470
18	Etanercept: a tumor necrosis factor inhibitor for psoriasis and psoriatic arthritis. Expert Review of Dermatology, 2006, 1, 527-534.	0.3	2
19	Once-Weekly Administration of High-Dosage Etanercept in Patients with Plaque Psoriasis: Results of a Pilot Experience (Power Study). International Journal of Immunopathology and Pharmacology, 2006, 19, 205873920601900.	1.0	28
20	Biological treatments for psoriasis. Therapy: Open Access in Clinical Medicine, 2006, 3, 425-436.	0.2	0
21	Infliximab in the treatment of psoriasis. Expert Review of Dermatology, 2006, 1, 515-526.	0.3	5
22	Skin Targets for New Biological Agents in Systemic Autoimmune Diseases. Handbook of Systemic Autoimmune Diseases, 2006, 5, 313-324.	0.1	0

#	ARTICLE	IF	CITATIONS
23	Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 060804053334002-???	1.3	34
24	Treatment of inflammatory dermatoses by tumour necrosis factor antagonists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 1171-1187.	1.3	26
25	Treatment of erythrodermic psoriasis with etanercept. <i>British Journal of Dermatology</i> , 2006, 155, 156-159.	1.4	49
26	Initial experience with routine administration of etanercept in psoriasis. <i>British Journal of Dermatology</i> , 2006, 155, 808-814.	1.4	41
27	Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 435-445.	1.1	43
28	Anti-TNF drugs in psoriasis and IBD - Where are we going?. <i>Future Prescriber</i> , 2006, 7, 14-20.	0.1	0
29	The long-term efficacy and safety of new biological therapies for psoriasis. <i>Archives of Dermatological Research</i> , 2006, 298, 7-15.	1.1	81
33	Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1572-1577.	0.5	101
34	Anti-Tumor Necrosis Factor Alpha-Induced Psoriasiform Eruptions: Three Further Cases and Current Overview. <i>Dermatology</i> , 2006, 213, 182-186.	0.9	54
35	Infections related to TNF- $\alpha$ inhibitors. <i>Expert Review of Dermatology</i> , 2006, 1, 737-749.	0.3	5
36	New treatments for psoriasis: Which biologic is best?. <i>Journal of Dermatological Treatment</i> , 2006, 17, 96-107.	1.1	23
37	The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. <i>Expert Opinion on Therapeutic Targets</i> , 2006, 10, 817-831.	1.5	27
38	Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. <i>Journal of Experimental Medicine</i> , 2007, 204, 3183-3194.	4.2	604
39	Outcomes in randomized controlled trials in psoriasis: What has changed over the last 20 years?. <i>Journal of Dermatological Treatment</i> , 2007, 18, 261-267.	1.1	17
40	Mechanism of Action, Pharmacokinetics, and Drug Interactions of Etanercept in Dermatology. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007, 11, S3-S13.	0.6	3
41	Efficacy of Etanercept in the Management of Plaque Psoriasis and Psoriatic Arthritis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007, 11, S14-S22.	0.6	0
42	Immune-mediated inflammatory diseases (IMiDs) and biologic therapy: a medical revolution. <i>Postgraduate Medical Journal</i> , 2007, 83, 251-260.	0.9	257
43	Measures used in specifying psoriasis lesion(s), global disease and quality of life: A systematic review. <i>Journal of Dermatological Treatment</i> , 2007, 18, 223-242.	1.1	38

#	ARTICLE	IF	CITATIONS
44	Etanercept and efalizumab treatment for high-severity psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. <i>Journal of Dermatological Treatment</i> , 2007, 18, 76-83.	1.1	27
45	Update on the epidemiology and systemic treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 171-185.	1.3	22
46	ETANERCEPT ATTENUATES THE DEVELOPMENT OF CERULEIN-INDUCED ACUTE PANCREATITIS IN MICE. <i>Shock</i> , 2007, 27, 542-551.	1.0	34
47	Long-Term Safety of Etanercept. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007, 11, S23-S36.	0.6	3
48	Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis. <i>Dermatology</i> , 2007, 215, 245-251.	0.9	64
49	Splanchnic ischemia and reperfusion injury is reduced by genetic or pharmacological inhibition of TNF- $\alpha$ . <i>Journal of Leukocyte Biology</i> , 2007, 81, 1032-1043.	1.5	29
50	Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis. <i>Archives of Dermatology</i> , 2007, 143, 719-26.	1.7	285
51	Practical Considerations for the Initiation and Maintenance of Etanercept in the Treatment of Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007, 11, S37-S47.	0.6	1
52	Efalizumab for the Treatment of Psoriatic Arthritis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007, 11, 57-66.	0.6	77
53	Biologic Agents in the Treatment of Psoriasis. <i>Recent Patents on Inflammation and Allergy Drug Discovery</i> , 2007, 1, 193-217.	3.9	5
54	Modeling the Exposure-Response Relationship of Etanercept in the Treatment of Patients With Chronic Moderate to Severe Plaque Psoriasis. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 238-248.	1.0	13
55	Developments in systemic immunomodulatory therapy for psoriasis. <i>Current Opinion in Pharmacology</i> , 2007, 7, 434-444.	1.7	15
56	A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 598-603.	0.6	142
58	Biologics in General Medicine. , 2007, , .		1
59	Anti-tumor necrosis factor therapies for psoriasis. <i>Expert Review of Dermatology</i> , 2007, 2, 335-349.	0.3	5
60	Efficacy and Safety of Etanercept in Psoriasis/Psoriatic Arthritis. <i>American Journal of Clinical Dermatology</i> , 2007, 8, 143-155.	3.3	53
63	Immunotargeting: A biological approach to the treatment of psoriasis. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2007, 4, 201-207.	0.5	0
64	An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 617-632.	0.9	42

#	ARTICLE	IF	CITATIONS
65	Update on infliximab: an intravenous biologic therapy for psoriasis. <i>Expert Review of Dermatology</i> , 2007, 2, 707-713.	0.3	3
66	Etanercept in psoriasis: the evidence of its therapeutic impact. <i>Core Evidence</i> , 0, Volume 2, 0-0.	4.7	1
67	Practical Management and Monitoring of Psoriasis Patients on Biologic Therapy: A Survey of Opinion Leaders and Practitioners. <i>Psoriasis Forum</i> , 2007, 13a, 4-12.	0.1	1
68	Tumor Necrosis Factor Blockade: Mechanism of Action. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2007, 12, 1-4.	0.8	35
69	Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. <i>British Journal of Dermatology</i> , 2007, 156, 138-142.	1.4	32
70	CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept. <i>British Journal of Dermatology</i> , 2007, 157, 1155-1160.	1.4	35
71	Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). <i>British Journal of Dermatology</i> , 2008, 158, 558-566.	1.4	633
72	TNF-Î± inhibitors. <i>Dermatologic Therapy</i> , 2007, 20, 251-264.	0.8	42
74	Cost-effectiveness of psoriasis therapy with etanercept in Germany. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007, 5, 762-768.	0.4	28
75	Biologic therapies in psoriasis: A new therapeutic approach. <i>Autoimmunity Reviews</i> , 2007, 6, 515-519.	2.5	83
76	Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double-blind, active drug-controlled study. <i>Arthritis and Rheumatism</i> , 2008, 58, 1921-1930.	6.7	71
77	Etanercept. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 491-502.	1.4	42
78	Etanercept: a new option in paediatric plaque psoriasis. <i>Future Prescriber</i> , 2008, 9, 6-10.	0.1	0
79	Chinese herbal medicine (Tuhuai extract) exhibits topical anti-proliferative and anti-inflammatory activity in murine disease models. <i>Experimental Dermatology</i> , 2008, 17, 681-687.	1.4	26
80	Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment. <i>Value in Health</i> , 2008, 11, 400-407.	0.1	56
81	Low-dose etanercept therapy in moderate to severe psoriasis in Korean. <i>Journal of Dermatology</i> , 2008, 35, 484-490.	0.6	19
82	Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome. <i>British Journal of Dermatology</i> , 2008, 158, 1098-1106.	1.4	26
83	Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. <i>British Journal of Dermatology</i> , 2008, 158, 1345-1349.	1.4	135

#	ARTICLE	IF	CITATIONS
84	Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies. <i>British Journal of Dermatology</i> , 2008, 159, 91-96.	1.4	19
85	Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2008, 159, 274-285.	1.4	129
86	Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2008, 159, 513-526.	1.4	182
87	Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. <i>British Journal of Dermatology</i> , 2008, 159, ???-???	1.4	149
88	Long-term data in the treatment of psoriasis. <i>British Journal of Dermatology</i> , 2008, 159, 18-24.	1.4	28
89	TNF $\alpha$ blockade in human diseases: An overview of efficacy and safety. <i>Clinical Immunology</i> , 2008, 126, 13-30.	1.4	224
90	Etanercept Treatment for Children and Adolescents with Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2008, 358, 241-251.	13.9	366
91	Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 125-135.	0.6	76
92	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 826-850.	0.6	1,128
93	To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 970-977.	0.6	28
94	Tumor necrosis factor antagonists in the therapy of psoriasis. <i>Clinics in Dermatology</i> , 2008, 26, 486-502.	0.8	50
95	Monitoring biologics for the treatment of psoriasis. <i>Clinics in Dermatology</i> , 2008, 26, 515-521.	0.8	5
96	Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. <i>Lancet, The</i> , 2008, 371, 1337-1342.	6.3	88
97	Targeting tumor necrosis factor $\alpha$ in psoriasis and psoriatic arthritis. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1085-1096.	1.5	58
98	Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. <i>Current Medical Research and Opinion</i> , 2008, 24, 1237-1254.	0.9	46
99	Adalimumab for the treatment of severe psoriasis and psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 363-370.	1.4	18
100	Etanercept: an overview of its role in the treatment of psoriasis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 305-310.	1.5	7
101	Etanercept at Different Dosages in the Treatment of Generalized Pustular Psoriasis: A Case Series. <i>Dermatology</i> , 2008, 216, 355-360.	0.9	36

#	ARTICLE	IF	CITATIONS
102	Serum Cytokines and Biomoral Immunological Characterization of Psoriatic Patients in Long Term Etanercept Treatment. <i>International Journal of Immunopathology and Pharmacology</i> , 2008, 21, 643-649.	1.0	14
103	Recent Advances in Inflammatory Skin Diseases. <i>Scottish Medical Journal</i> , 2008, 53, 30-34.	0.7	6
104	The Combination of Etanercept and Methotrexate Increases the Effectiveness of Treatment in Active Psoriasis Despite Inadequate Effect of Methotrexate Therapy. <i>Acta Dermato-Venereologica</i> , 2008, 88, 495-501.	0.6	123
105	Treatment of Psoriasis. , 2008, , .		3
107	Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. <i>Expert Review of Dermatology</i> , 2008, 3, 657-665.	0.3	44
108	Drugs that act on the immune system: cytokines and monoclonal antibodies. <i>Side Effects of Drugs Annual</i> , 2008, 30, 435-451.	0.6	3
109	Keynote lecture: psoriasis update. <i>Expert Review of Dermatology</i> , 2008, 3, S3-S9.	0.3	0
110	Biological drugs targeting the immune response in the therapy of psoriasis. <i>Biologics: Targets and Therapy</i> , 2008, 2, 687.	3.0	16
111	Emerging treatments in the management of psoriasis: biological targeting with ustekinumab. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2009, 2, 95.	0.8	0
112	A cost&ndash;utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy. <i>ClinicoEconomics and Outcomes Research</i> , 2009, 1, 53.	0.7	15
113	Biologics in the management of psoriasis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2009, 2, 111.	0.8	8
114	Can Adalimumab Make a Smooth and Easy Transition from Cyclosporine a Reality? A Case Series of Successful Transitions. <i>Psoriasis Forum</i> , 2009, 15a, 33-35.	0.1	6
115	Clinical Review a Practical Approach to the Use of Etanercept. <i>Psoriasis Forum</i> , 2009, 15a, 36-40.	0.1	0
116	CCR6 is required for IL-23&#x201c;induced psoriasis-like inflammation in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 2317-2329.	3.9	207
117	Etanercept in the treatment of plaque psoriasis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2009, 2, 77.	0.8	10
118	Cost-effectiveness of&#x201c;biologics for&#x201c;moderate-to-severe psoriasis from the&#x201c;perspective of&#x201c;the&#x201c;Swiss healthcare system. <i>European Journal of Dermatology</i> , 2009, 19, 494-499.	0.3	15
119	Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update. <i>Journal of Inflammation Research</i> , 2009, 2, 29.	1.6	7
120	Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. <i>Current Medical Research and Opinion</i> , 2009, 25, 2311-2316.	0.9	23

#	ARTICLE	IF	CITATIONS
121	Ustekinumab for the treatment of plaque psoriasis. <i>Expert Review of Dermatology</i> , 2009, 4, 443-453.	0.3	1
122	Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study. <i>Journal of Dermatological Treatment</i> , 2009, 20, 354-358.	1.1	9
123	Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor $\pm$ therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 209-215.	0.5	200
124	Management of Severe Psoriasis with TNF Antagonists. <i>Current Problems in Dermatology</i> , 2009, 38, 107-136.	0.8	22
125	Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis. <i>Dermatology</i> , 2009, 219, 209-218.	0.9	87
127	TNF-Alpha as a Therapeutic Target in Inflammatory Diseases, Ischemia- Reperfusion Injury and Trauma. <i>Current Medicinal Chemistry</i> , 2009, 16, 3152-3167.	1.2	236
129	Biologic Therapies for Psoriasis. <i>Journal of rheumatology Supplement, The</i> , 2009, 83, 62-64.	2.2	2
130	Biologics in the Treatment of Psoriasis: Clinical and Economic Overview. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, S49-S57.	0.6	22
131	Use of Biologic Therapeutics in Difficult-to-Treat Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, 6-17.	0.6	0
133	Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis. <i>International Journal of Dermatology</i> , 2009, 48, 653-658.	0.5	19
134	Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study. <i>Journal of Dermatology</i> , 2009, 36, 191-196.	0.6	6
135	Economic evaluation of etanercept in the management of chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2009, 160, 380-386.	1.4	26
136	Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. <i>British Journal of Dermatology</i> , 2009, 160, 162-169.	1.4	48
137	Using "number needed to treat" to help conceptualize the magnitude of benefit and risk of tumour necrosis factor- $\pm$ inhibitors for patients with severe psoriasis. <i>British Journal of Dermatology</i> , 2009, 161, 605-616.	1.4	14
138	Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. <i>British Journal of Dermatology</i> , 2009, 161, 1190-1195.	1.4	58
139	Experience with biologics for psoriasis in daily practice: switching is worth a try. <i>British Journal of Dermatology</i> , 2009, 161, 948-951.	1.4	34
140	British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. <i>British Journal of Dermatology</i> , 2009, 161, 987-1019.	1.4	412
141	Long-term efficacy of biologics in dermatology. <i>Dermatologic Therapy</i> , 2009, 22, 22-33.	0.8	28



#	ARTICLE	IF	CITATIONS
142	Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?. <i>Dermatologic Therapy</i> , 2009, 22, 431-440.	0.8	40
143	Etanercept: Efficacy and safety. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 402-405.	1.3	14
144	Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 896-904.	1.3	109
145	Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1374-1382.	1.3	88
146	European S3 Guidelines on the systemic treatment of psoriasis vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1-70.	1.3	683
147	Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis. <i>Dermatology</i> , 2009, 219, 239-249.	0.9	48
148	Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 386-413.	0.2	73
149	Eficiencia de los agentes biológicos en el tratamiento de la psoriasis moderada-grave. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 792-803.	0.2	19
150	Cutaneous side effects of anti-tumor necrosis factor biologic therapy: A clinical review. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 486-504.	0.6	166
151	Thrombocytopenia associated with the use of anti-tumor necrosis factor agents for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 781-785.	0.6	35
153	Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 386-413.	0.2	14
154	Efficiency of Biologic Agents in the Treatment of Moderate to Severe Psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 792-803.	0.2	4
155	Ustekinumab. <i>Drugs</i> , 2009, 69, 1141-1152.	4.9	30
156	Efalizumab Therapy for Psoriasis in Patients with Inadequate Responses to Etanercept. <i>American Journal of Clinical Dermatology</i> , 2009, 10, 134-140.	3.3	0
157	Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments. <i>American Journal of Clinical Dermatology</i> , 2009, 10, 319-324.	3.3	69
159	Tratamiento de la psoriasis en placas moderada y grave con etanercept. <i>Piel</i> , 2009, 24, 105-113.	0.0	4
161	Advances in the use of biologic agents for the treatment of systemic vasculitis. <i>Current Opinion in Rheumatology</i> , 2009, 21, 3-9.	2.0	31
162	Influence and Variation of the Body Mass Index in Patients Treated with Etanercept for Plaque-Type Psoriasis. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 219-225.	1.0	41

#	ARTICLE	IF	CITATIONS
163	Practice of Phototherapy in the Treatment of Moderate-to-Severe Psoriasis. <i>Current Problems in Dermatology</i> , 2009, 38, 59-78.	0.8	14
164	Angiogenesis in Psoriatic Skin and its Modifications after Administration of Etanercept: Videocapillaroscopic, Histological and Immunohistochemical Evaluation. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 371-377.	1.0	52
165	Efficacy and safety of Etanercept in children and adolescents aged 6-18 years with severe plaque psoriasis. <i>European Journal of Dermatology</i> , 2010, 20, 323-328.	0.3	15
166	Treatment of Psoriasis with Different Dosage Regimens of Etanercept: Preliminary Results from the TIRA Plastic Study Group. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 797-802.	1.0	22
167	Current treatment options in the management of psoriasis. <i>The Prescriber</i> , 2010, 21, 31-44.	0.1	2
168	Cost-effectiveness analysis of TNF- $\alpha$ blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. <i>Dermatologic Therapy</i> , 2010, 23, S7-S13.	0.8	17
169	Retrospective analysis of systemic treatments for psoriasis patients attending a Psocare center in Florence. Relevance of biological drugs use and comorbidities. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 555-560.	1.3	7
170	Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1135-1143.	1.3	28
171	Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with high need psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1413-1420.	1.3	14
172	EADV preceptorship: advances in dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 2-24.	1.3	11
173	Comparing biological therapies in psoriasis: implications for clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 10-14.	1.3	26
174	Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. <i>British Journal of Pharmacology</i> , 2010, 160, 810-820.	2.7	120
175	Safety profile of intravenous and subcutaneous sipilizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies. <i>International Journal of Dermatology</i> , 2010, 49, 818-828.	0.5	23
176	Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. <i>British Journal of Dermatology</i> , 2010, 162, 1349-1358.	1.4	39
177	Update of the management of chronic psoriasis: new approaches and emerging treatment options. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2010, 3, 25.	0.8	4
178	Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. <i>Core Evidence</i> , 2010, 5, 11.	4.7	11
179	Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. <i>Rheumatology</i> , 2010, 49, 1949-1956.	0.9	40
180	Immunomodulation in Dermatology. , 2010, , 29-38.		0

#	ARTICLE	IF	CITATIONS
181	Evaluation of a Range of Anti-Proliferative Assays for the Preclinical Screening of Anti-Psoriatic Drugs: A Comparison of Colorimetric and Fluorimetric Assays with the Thymidine Incorporation Assay. <i>Assay and Drug Development Technologies</i> , 2010, 8, 384-395.	0.6	14
182	Cost-Effectiveness of Biological Therapy in Remission Induction of Moderate to Severe Plaque Psoriasis. <i>Dermatology</i> , 2010, 221, 236-242.	0.9	21
183	Clinically validated approaches to the treatment of autoimmune diseases. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 195-213.	1.9	26
184	Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis. <i>Current Medical Research and Opinion</i> , 2010, 26, 2287-2300.	0.9	10
186	Treating Psoriasis with Etanercept in Italian Clinical Practice. <i>Clinical Drug Investigation</i> , 2010, 30, 507-516.	1.1	12
187	Long-term Safety and Efficacy of Etanercept in the Treatment of Psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 47-53.	0.2	4
188	Sudden Onset of Viral Warts During Treatment With Etanercept. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 460-462.	0.2	0
189	Treatment of Scalp Psoriasis: Review of the Evidence and Delphi Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 827-846.	0.2	6
190	Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti-Tumor Necrosis Factor Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 1048-1055.	2.4	158
191	Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 228-234.	0.6	46
192	Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 580-586.	0.6	20
193	Intermittent etanercept therapy in pediatric patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 769-774.	0.6	42
194	Long-term etanercept in pediatric patients with plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 762-768.	0.6	96
195	A new era in the management of psoriasis? The biologics: facts and controversies. <i>Clinics in Dermatology</i> , 2010, 28, 81-87.	0.8	30
199	Safety and Efficacy of the Tumor Necrosis Factor Antagonists. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 35-47.	1.6	36
200	Seguridad y eficacia de etanercept a largo plazo en el tratamiento de la psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 47-53.	0.2	6
201	Aparición brusca de verrugas virales durante el tratamiento con etanercept. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 460-462.	0.2	4
202	Tratamiento de la psoriasis del cuero cabelludo. Revisión de la evidencia y Consenso Delphi del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 827-846.	0.2	13

#	ARTICLE	IF	CITATIONS
203	Etanercept: An Evolving Role in Psoriasis and Psoriatic Arthritis. <i>American Journal of Clinical Dermatology</i> , 2010, 11, 3-9.	3.3	4
204	Comparative Effectiveness Without Head-to-Head Trials. <i>Pharmacoeconomics</i> , 2010, 28, 935-945.	1.7	247
205	Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1105-1112.	1.4	5
206	Advances in the treatment of moderate-to-severe plaque psoriasis. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 795-806.	0.5	27
207	Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 183-191.	0.6	8
209	Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis. <i>Reumatología Clínica (English Edition)</i> , 2011, 7, 179-188.	0.2	8
211	The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 1035-1050.	0.6	197
212	Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2011, 165, 661-668.	1.4	128
213	Adverse effects of biologics: a network meta-analysis and Cochrane overview. <i>The Cochrane Library</i> , 2016, 2016, CD008794.	1.5	481
214	Ustekinumab: differential use in psoriasis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2011, 4, 93.	0.8	4
215	Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. <i>Drug Design, Development and Therapy</i> , 2011, 5, 41.	2.0	18
216	Care of Generalized Psoriasis in Elderly Patients beyond Topical Therapy: A Review and a Proposed Algorithm. <i>Psoriasis Forum</i> , 2011, 17a, 105-116.	0.1	0
218	Combined treatment with etanercept 50Âmg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis. <i>European Journal of Dermatology</i> , 2011, 21, 568-572.	0.3	32
219	Long-term, continuous dosing of etanercept in patients with plaque psoriasis. <i>Expert Review of Dermatology</i> , 2011, 6, 361-373.	0.3	1
220	Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. <i>British Journal of Dermatology</i> , 2011, 165, 640-645.	1.4	51
221	Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2011, 165, 652-660.	1.4	120
222	Etanercept: effectiveness and safety data of a retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1113-1115.	1.3	9
223	S3 - Guidelines on the treatment of psoriasis vulgaris Update 2011. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, S1-S95.	0.4	66

#	ARTICLE	IF	CITATIONS
225	Anti-cytokine therapies for psoriasis. <i>Experimental Cell Research</i> , 2011, 317, 1293-1300.	1.2	51
226	Anti-tumor necrosis factor therapies for immune-mediated and inflammatory skin diseases. <i>Drug Development Research</i> , 2011, 72, 615-622.	1.4	1
227	Etanercept overview of clinical experience in the treatment of psoriasis and psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 135-155.	0.3	3
228	Canadian Guidelines for the Management of Plaque Psoriasis: Overview. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011, 15, 210-219.	0.6	76
229	Integrated Population Pharmacokinetics of Etanercept in Healthy Subjects and in Patients With Rheumatoid Arthritis Ankylosing Spondylitis. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 864-875.	1.0	17
230	Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 864-71.	3.8	259
232	TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2012, 132, 593-600.	0.3	148
233	Putting together the psoriasis puzzle: an update on developing targeted therapies. <i>DMM Disease Models and Mechanisms</i> , 2012, 5, 423-433.	1.2	111
234	Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1143-1150.	0.5	129
235	The Epidermis as an Adjuvant. <i>Journal of Investigative Dermatology</i> , 2012, 132, 940-948.	0.3	56
236	Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2012, 22, 532-540.	0.9	24
237	Efficacy and Safety of Clinical Use of Etanercept for the Treatment of Moderate-to-Severe Psoriasis in Spain: Results of a Multicentric Prospective Study at 12 Months Follow-Up. <i>Dermatology</i> , 2012, 225, 220-230.	0.9	13
238	Etanercept Improves Quality of Life Outcomes and Treatment Satisfaction in Patients with Moderate to Severe Plaque Psoriasis in Clinical Practice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2012, 16, 407-416.	0.6	9
239	A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2012, 167, 649-657.	1.4	116
240	Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment. <i>Archives of Dermatological Research</i> , 2012, 304, 707-717.	1.1	24
241	Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses. <i>Dermatology and Therapy</i> , 2012, 2, 9.	1.4	29
242	Psoriasis: Ustekinumab and Other Biologics in the Pipeline. <i>Current Dermatology Reports</i> , 2012, 1, 108-114.	1.1	1
243	Nonserious Infections. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 707-725.	0.8	16

#	ARTICLE	IF	CITATIONS
244	A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. <i>Journal of Dermatological Treatment</i> , 2012, 23, 261-267.	1.1	47
245	Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 911-921.	1.0	19
246	Paradoxical inflammation induced by anti-TNF agents in patients with IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 496-503.	8.2	169
247	Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, e33-e45.	0.6	89
248	Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 241-251.	0.6	157
249	Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 369-375.	0.6	158
250	Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 731-741.	0.6	101
251	Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 86-92.	0.6	91
252	Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 245-256.	0.6	71
253	Comparison of Ustekinumab With Other Biological Agents for the Treatment of Moderate to Severe Plaque Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 1403.	1.7	64
254	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. <i>British Journal of Dermatology</i> , 2012, 166, 861-872.	1.4	121
255	Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. <i>British Journal of Dermatology</i> , 2012, 167, 3-11.	1.4	85
256	Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2012, 167, 12-20.	1.4	38
257	Current and Emerging Systemic Treatment Strategies for Psoriasis. <i>Drugs</i> , 2012, 72, 1867-1880.	4.9	35
258	The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 642-650.	0.6	52
259	Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 1349-1361.	0.6	40
260	Power of crowdsourcing: Novel methods of data collection in psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 1273-1281.e9.	0.6	18
261	IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 145-154.e9.	1.5	320

#	ARTICLE	IF	CITATIONS
262	Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research. <i>Value in Health</i> , 2012, 15, 940-947.	0.1	290
263	Cost Per Responder Associated with Biologic Therapies for Crohn's Disease, Psoriasis, and Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2012, 29, 620-634.	1.3	56
264	Emerging Adverse Cutaneous Drug Reactions. <i>Dermatologic Clinics</i> , 2012, 30, 695-730.	1.0	4
265	Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis. <i>Applied Health Economics and Health Policy</i> , 2012, 10, 343-353.	1.0	14
266	Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1252-1261.	1.3	56
267	Comparative Efficacy of Biologics in Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 365-374.	3.3	52
268	Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy. <i>PLoS ONE</i> , 2012, 7, e33486.	1.1	92
269	Ustekinumab Improves Psoriasis without Altering T Cell Cytokine Production, Differentiation, and T Cell Receptor Repertoire Diversity. <i>PLoS ONE</i> , 2012, 7, e51819.	1.1	22
270	Biologics in the treatment of psoriasis and emerging new therapies in the pipeline. <i>Psoriasis: Targets and Therapy</i> , 2012, , 29.	1.2	2
271	Psoriasis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2012, 7, 385-422.	9.6	412
272	Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. <i>European Journal of Health Economics</i> , 2012, 13, 145-156.	1.4	17
273	Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 448-455.	1.3	21
274	Cost-effectiveness of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 768-777.	1.3	31
275	Implementing treatment goals for successful long-term management of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 12-20.	1.3	70
276	Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 21-29.	1.3	21
277	Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1331-1344.	1.3	58
278	Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2012, 166, 179-188.	1.4	177
279	Long-term efficacy of etanercept for psoriasis in daily practice. <i>British Journal of Dermatology</i> , 2012, 166, 445-447.	1.4	17

#	ARTICLE	IF	CITATIONS
280	S3 " Guidelines on the treatment of psoriasis vulgaris (English version). Update. JDDG - Journal of the German Society of Dermatology, 2012, 10, S1-95.	0.4	235
281	Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab <sup>®</sup> certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. British Journal of Dermatology, 2012, 167, 180-190.	1.4	131
282	Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 2-8.	1.3	8
283	Is "class effect"™ relevant when assessing the benefit/risk profile of a biologic agent?. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 9-16.	1.3	9
284	German S3-guidelines on the treatment of psoriasis vulgaris (short version). Archives of Dermatological Research, 2012, 304, 87-113.	1.1	96
285	Etanercept use for psoriasis in Taiwan: a case series study. International Journal of Dermatology, 2013, 52, 673-680.	0.5	7
286	Patient preferences for psoriasis treatments: impact of treatment experience. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 187-198.	1.3	55
287	Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 593-600.	1.3	32
288	Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. Journal of Dermatological Treatment, 2013, 24, 193-198.	1.1	38
289	A randomized, "head-to-head"™ pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 899-906.	1.3	34
290	Cost Effectiveness of Biologic Therapies for Plaque Psoriasis. American Journal of Clinical Dermatology, 2013, 14, 315-326.	3.3	55
291	Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring. Clinical Reviews in Allergy and Immunology, 2013, 44, 121-140.	2.9	69
292	Etanercept in the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy, 2013, 13, 1441-1450.	1.4	7
293	Psoriasis, Anti-Tumor Necrosis Factor Therapy, and Tuberculosis: Report of Three Challenging Cases and Literature Review. Infectious Diseases and Therapy, 2013, 2, 59-73.	1.8	10
295	Biological therapies for psoriasis. Expert Opinion on Biological Therapy, 2013, 13, 1715-1730.	1.4	23
297	Chronic hepatitis C virus hepatitis and psoriasis: No longer a contraindication to interferon use in the era of biological agents?. Scandinavian Journal of Infectious Diseases, 2013, 45, 320-323.	1.5	7
298	The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends in Immunology, 2013, 34, 174-181.	2.9	399
299	Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Annals of the Rheumatic Diseases, 2013, 72, 165-178.	0.5	315



#	ARTICLE	IF	CITATIONS
300	OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 756-764.	0.6	31
302	Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment. <i>Actas Dermo-sifilograficas</i> , 2013, 104, 694-709.	0.2	32
303	Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept. <i>Dermatologica Sinica</i> , 2013, 31, 11-18.	0.2	11
304	Biologic systemic therapy for moderate-to-severe psoriasis: A review. <i>Journal of Taibah University Medical Sciences</i> , 2013, 8, 142-150.	0.5	4
305	Anti-cytokine therapy in the treatment of psoriasis. <i>Cytokine</i> , 2013, 61, 704-712.	1.4	42
306	Novel colloidal carriers for psoriasis: Current issues, mechanistic insight and novel delivery approaches. <i>Journal of Controlled Release</i> , 2013, 170, 380-395.	4.8	139
307	Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 57-63.	0.6	16
308	Biological treatments for moderate-to-severe psoriasis: indirect comparison. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 121-130.	0.7	37
309	Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 949-958.	1.3	56
310	Immunogenicity of anti-TNF $\pm$ therapy in psoriasis: a clinical issue?. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1673-1682.	1.4	56
311	Treatment of Psoriasis and Psoriatic Arthritis. <i>BioDrugs</i> , 2013, 27, 3-12.	2.2	42
312	Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States. <i>Pharmacoeconomics</i> , 2013, 31, 823-839.	1.7	27
313	The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). <i>Journal of Dermatological Treatment</i> , 2013, 24, 169-178.	1.1	59
314	A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. <i>British Journal of Dermatology</i> , 2013, 168, 1080-1087.	1.4	77
315	One-Year, Multicenter, Open-Label, Single-Arm Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Moderate-to-Severe Plaque Psoriasis in a Canadian Population. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013, 17, 129-138.	0.6	8
316	Psoriasis Vulgaris: An Evidence-Based Guide for Primary Care. <i>Journal of the American Board of Family Medicine</i> , 2013, 26, 787-801.	0.8	25
317	The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials. <i>British Journal of Dermatology</i> , 2013, 169, 1198-1206.	1.4	15
318	Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence. <i>Journal of Dermatological Treatment</i> , 2013, 24, 199-208.	1.1	16

#	ARTICLE	IF	CITATIONS
319	Dose Response and Pharmacokinetics of Tofacitinib (CPâ€690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-8.	1.3	4
320	Etanercept for the treatment of psoriasis. Expert Review of Dermatology, 2013, 8, 357-372.	0.3	4
321	Incomplete Data in Randomized Dermatology Trials: Consequences and Statistical Methodology. Dermatology, 2013, 226, 19-27.	0.9	6
322	Clinical and economic impact of etanercept in real-life: A prospective, non-interventional study of etanercept in the treatment of patients with moderate to severe plaque psoriasis in private dermatologist settings (ESTHER). European Journal of Dermatology, 2013, 23, 774-781.	0.3	7
323	Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials. Cadernos De Saude Publica, 2013, 29, s17-s31.	0.4	4
324	Systemic Lupus Erythematosus and Psoriasis: Comparison of Immunopathogenesis. Psoriasis Forum, 2013, 19a, 165-175.	0.1	1
325	Tumor Necrosis Factor-Î± Triad: Psoriasis, Cardiovascular Disease, and Depression. Psoriasis Forum, 2013, 19a, 41-49.	0.1	3
326	Efficacy and Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis: A Meta-Analysis and Cost-Efficacy Analysis Using the Intention-to-Treat Principle. BioMed Research International, 2014, 2014, 1-10.	0.9	24
327	Optimal dose of etanercept in the treatment of rheumatoid arthritis. Open Access Rheumatology: Research and Reviews, 2014, 6, 27.	0.8	0
328	Unmet needs in the treatment of psoriasis. European Journal of Dermatology, 2014, 24, 523-532.	0.3	24
329	Disease characteristics in patients with and without psoriatic arthritis treated with etanercept. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 581-589.	1.3	13
330	Efficacy of biologics in the treatment of moderateâ€toâ€severe plaque psoriasis: a systematic review and metaâ€analysis of randomized controlled trials with different time points. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1633-1653.	1.3	65
331	Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis. American Journal of Clinical Dermatology, 2014, 15, 467-478.	3.3	48
332	Efficacy and safety of etanercept in chronic immune-mediated disease. Expert Opinion on Drug Safety, 2014, 13, 649-661.	1.0	24
333	Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics: Targets and Therapy, 2014, 8, 169.	3.0	33
334	Network Meta-analysis of Treatments for Chronic Plaque Psoriasis in Canada. Journal of Cutaneous Medicine and Surgery, 2014, 18, 371-378.	0.6	14
335	Biologic Agents for Moderate-to-Severe Plaque Psoriasis. Journal of the Dermatology Nurses' Association, 2014, 6, S12-S30.	0.1	0
336	Patch Test Results in Psoriasis Patients on Biologics. Dermatitis, 2014, 25, 182-190.	0.8	19

#	ARTICLE	IF	CITATIONS
337	Biologic Agents for Moderate-to-Severe Plaque Psoriasis. Journal of the Dermatology Nurses' Association, 2014, 6, 178-196.	0.1	0
338	The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology, 2014, 53, 213-222.	0.9	177
339	Serum Levels of TNF- $\alpha$ , IL-12/23p40, and IL-17 in Plaque Psoriasis and Their Correlation with Disease Severity. Journal of Immunology Research, 2014, 2014, 1-9.	0.9	55
340	Combined Use of Systemic Agents for Psoriasis. JAMA Dermatology, 2014, 150, 1213.	2.0	34
341	JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis. Journal of Immunology Research, 2014, 2014, 1-7.	0.9	102
342	Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 333-337.	1.3	217
343	Efficacy and safety of systemic treatments for moderate to severe psoriasis: meta-analysis of randomized controlled trials. British Journal of Dermatology, 2014, 170, 274-303.	1.4	141
344	Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody. Journal of Immunology, 2014, 192, 3828-3836.	0.4	130
345	Cost-effectiveness of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system. International Journal of Dermatology, 2014, 53, 1151-1156.	0.5	13
346	Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1424-1430.	1.3	57
347	Psoriasis. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a015354-a015354.	2.9	233
348	Antidrug antibodies in psoriasis: a systematic review. British Journal of Dermatology, 2014, 170, 261-273.	1.4	143
350	Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases. Drugs, 2014, 74, 1379-1410.	4.9	87
351	Drug therapies in dermatology. Clinical Medicine, 2014, 14, 47-53.	0.8	7
352	A consensus report on appropriate treatment optimization and transitioning in the management of moderate to severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 438-453.	1.3	122
353	Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA. Journal of Dermatological Treatment, 2014, 25, 54-56.	1.1	21
355	Systematic review on the maintenance of response during systemic antipsoriatic therapy. British Journal of Dermatology, 2015, 173, 910-921.	1.4	6
356	Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. British Journal of Dermatology, 2015, 173, 510-518.	1.4	87

#	ARTICLE	IF	CITATIONS
357	Biologics in dermatology: adverse effects. <i>International Journal of Dermatology</i> , 2015, 54, 1442-1460.	0.5	14
358	Etanercept Inhibits Pro-inflammatory Cytokines Expression in Titanium Particle-Stimulated Peritoneal Macrophages. <i>Tropical Journal of Pharmaceutical Research</i> , 2015, 14, 983.	0.2	1
359	Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2015, 21, 201-209.	0.5	55
360	Etanercept Combined With Systemic Drugs or Phototherapy for Treatment of Psoriasis. <i>Actas Dermo-sifiliogrÁficas</i> , 2015, 106, 180-188.	0.2	1
361	Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2641-2648.	0.3	116
362	Biologic Agents for Psoriasis. , 2015, , 1411-1420.		0
363	The 5-point Investigatorâ€™s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. <i>Journal of Dermatological Treatment</i> , 2015, 26, 23-31.	1.1	173
364	Saudi practical guidelines on biologic treatment of psoriasis. <i>Journal of Dermatological Treatment</i> , 2015, 26, 223-229.	1.1	16
365	Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 589-598.	0.6	54
366	Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the <scp>CRYSTEL</scp> study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 468-473.	1.3	11
368	Subcutaneous Biological Treatments for Moderate to Severe Psoriasis: Interpreting Safety Data by Network Meta-Analysis. <i>Drugs - Real World Outcomes</i> , 2015, 2, 23-27.	0.7	8
369	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 400-409.	0.6	472
370	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and Tj ETQq0 0 0 rgBT /Overlock 10	6.3	719
371	Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1576-1581.	1.3	5
372	Biologic Response Modifiers and Pediatric Psoriasis. <i>Pediatric Dermatology</i> , 2015, 32, 303-320.	0.5	18
373	Tratamiento combinado con etanercept y fÃ¡rmacos sistÃ©micos/fototerapia en psoriasis. <i>Actas Dermo-sifiliogrÁficas</i> , 2015, 106, 180-188.	0.2	2
374	Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic. <i>Journal of Dermatological Treatment</i> , 2015, 26, 493-501.	1.1	21
375	Immunogenicity of Biologic Treatments for Psoriasis: Therapeutic Consequences and the Potential Value of Concomitant Methotrexate. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 285-294.	3.3	41

#	ARTICLE	IF	CITATIONS
376	Interleukin-17 Antagonists in the Treatment of Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 109-114.	0.6	13
377	Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 561-569.	0.6	1
378	Long-Term Efficacy of Etanercept for Plaque-Type Psoriasis and Estimated Cost in Daily Clinical Practice. <i>Value in Health</i> , 2015, 18, 1158-1161.	0.1	10
379	Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response. <i>British Journal of Dermatology</i> , 2015, 172, 504-512.	1.4	62
380	Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study. <i>Acta Dermato-Venereologica</i> , 2016, 96, 251-252.	0.6	21
381	Biologic Therapy in Psoriasis: Safety Profile. <i>Current Drug Safety</i> , 2016, 11, 4-11.	0.3	27
382	Treatment challenges in the management of moderate-to-severe plaque psoriasis &ndash; role of secukinumab. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2016, Volume 9, 347-355.	0.8	11
383	Anti-TNF- $\alpha$ Drugs Differently Affect the TNF- $\alpha$ -sTNFR System and Monocyte Subsets in Patients with Psoriasis. <i>PLoS ONE</i> , 2016, 11, e0167757.	1.1	27
385	An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1730-1741.	1.3	7
386	Treatment of psoriasis with etanercept: the typical patient profile. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1092-1099.	1.3	17
387	Tumour necrosis factor- $\alpha$ plays a significant role in the Aldara-induced skin inflammation in mice. <i>British Journal of Dermatology</i> , 2016, 174, 1011-1021.	1.4	17
388	Serbian Association of Dermatovenereologistsâ€™ Guidelines for the Diagnosis and Treatment of Psoriasis. <i>Serbian Journal of Dermatology and Venereology</i> , 2016, 8, 61-78.	0.2	1
389	Etanercept and methotrexate combination therapy for the treatment of moderate to severe psoriasis: A retrospective multicentre study. <i>Australasian Journal of Dermatology</i> , 2016, 57, e147-e148.	0.4	2
390	Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. <i>International Journal of Women's Dermatology</i> , 2016, 2, 151-153.	1.1	12
391	Review of maintenance of response to psoriasis treatments. <i>Journal of Dermatological Treatment</i> , 2016, 27, 293-297.	1.1	11
392	A Review of Psoriasis, Therapies, and Suicide. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 293-303.	0.6	37
393	Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1584-1591.	0.3	63
394	Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 612-618.e6.	0.6	48

#	ARTICLE	IF	CITATIONS
395	Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study. <i>Dermatology</i> , 2016, 232, 407-414.	0.9	13
396	Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1423-1433.	1.3	10
397	Antigen dynamics govern the induction of CD4 + T cell tolerance during autoimmunity. <i>Journal of Autoimmunity</i> , 2016, 72, 84-94.	3.0	4
398	Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 740-746.	0.6	20
399	A randomized phase 2b trial of baricitinib, an oral Janus kinase (<sc>JAK</sc>) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2016, 174, 1266-1276.	1.4	207
400	A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50Âmg twice weekly followed by etanercept 25Âmg twice weekly, the combination of etanercept 25Âmg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis. <i>BMC Dermatology</i> , 2016, 16, 11.	2.1	21
401	Review of Available and Investigational Biologics and Non-Biologic Small Molecules for the Treatment of Plaque Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016, 2, 11-21.	0.3	3
402	Biologic Therapy for Psoriasis. , 2016, , 281-294.		0
403	A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 332-338.	1.1	61
404	Treatment of psoriasis. , 2016, , 43-84.		0
405	Immunopathogenesis of Psoriasis Skin and Nail. , 2016, , 45-52.		0
406	Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 147-162.	3.3	20
407	Secukinumab (AIN-457) for the treatment of Psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 187-202.	1.3	10
408	Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and) Tj ETQq1 1 0.784316.rgBT /Overlock 107		
409	Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. <i>Rheumatology International</i> , 2016, 36, 603-612.	1.5	54
410	Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review. <i>Journal of Dermatological Treatment</i> , 2016, 27, 406-413.	1.1	26
411	Anti-interleukin-17 treatment of psoriasis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 311-315.	1.1	12
413	TNF-Î± in a molecularly targeted therapy of psoriasis and psoriatic arthritis. <i>Postgraduate Medical Journal</i> , 2016, 92, 172-178.	0.9	19

#	ARTICLE	IF	CITATIONS
414	Psoriatic Arthritis and Psoriasis. , 2016, , .		3
415	Efficacy and cost of etanercept in long-term psoriasis: Rational use in clinical practice. Journal of Dermatological Treatment, 2016, 27, 37-42.	1.1	4
416	Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective. Australasian Journal of Dermatology, 2016, 57, 137-140.	0.4	31
417	A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. British Journal of Dermatology, 2017, 176, 577-593.	1.4	53
418	Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. British Journal of Dermatology, 2017, 176, 594-603.	1.4	55
419	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatorâ€“controlled VOYAGE 1 trial. Journal of the American Academy of Dermatology. 2017, 76, 405-417.	0.6	673
420	The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar. Current Medical Research and Opinion, 2017, 33, 993-1003.	0.9	25
421	Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study. Journal of Dermatological Treatment, 2017, 28, 606-612.	1.1	8
422	Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria. JDDG -Journal of the German Society of Dermatology, 2017, 15, 309-317.	0.4	6
423	Italian guidelines on the systemic treatments of moderateâ€“toâ€“severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 774-790.	1.3	140
424	Treatment history of patients receiving biologic therapy for psoriasis â€“ a Danish nationwide study. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e362-e363.	1.3	15
425	Etanercept, Adalimumab und Ustekinumab bei Psoriasis: Analyse von 209 Behandlungsreihen in Ã–sterreich. JDDG - Journal of the German Society of Dermatology, 2017, 15, 309-318.	0.4	2
426	Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab. British Journal of Dermatology, 2017, 177, 411-418.	1.4	11
427	Current Practice of Therapeutic Drug Monitoring of Biopharmaceuticals in Psoriasis Patients. Therapeutic Drug Monitoring, 2017, 39, 356-359.	1.0	13
428	Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis. Pharmacogenomics, 2017, 18, 631-638.	0.6	25
429	Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. Journal of Investigative Dermatology, 2017, 137, 1646-1654.	0.3	108
430	TNF Inhibitors for Psoriasis and Psoriatic Arthritis. Current Dermatology Reports, 2017, 6, 113-120.	1.1	1
431	Immunopathogenesis of Psoriasis. , 2017, , 373-395.		4

#	ARTICLE	IF	CITATIONS
432	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE) Tj ETQq0 0.0rgBT /Oyeplock 10	6.3	428
433	Drug concentration and antidrug antibodies in patients with psoriasis treated with adalimumab or etanercept. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e518-e519.	1.3	3
434	Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 1537-1551.	1.4	43
435	Biologic Therapy in the Treatment of Chronic Skin Disorders. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 315-327.	0.7	2
436	Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 70-85.	2.3	7
437	Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 2S-40S.	0.6	9
438	Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2247-2259.	1.4	87
439	Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis. <i>Journal of Medical Economics</i> , 2017, 20, 1224-1230.	1.0	23
440	Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-12.	1.4	55
441	Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Drugs in R and D</i> , 2017, 17, 29-51.	1.1	33
442	The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 928-938.	1.4	155
443	Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2017, 176, 890-901.	1.4	107
444	An IL-17â€‘dominant immune profile is shared across the major orphan forms of ichthyosis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 152-165.	1.5	135
445	Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>British Journal of Dermatology</i> , 2017, 176, 1297-1307.	1.4	50
446	Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. <i>Annual Review of Medicine</i> , 2017, 68, 255-269.	5.0	134
447	A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study. <i>British Journal of Dermatology</i> , 2017, 176, 624-633.	1.4	40
448	Efficacies of biological therapies at week 12 in patients with plaque psoriasis in real-world academic clinical practice: a Canadian multicentre retrospective study. <i>British Journal of Dermatology</i> , 2017, 177, 297-298.	1.4	1
449	Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study. <i>Current Medical Science</i> , 2017, 37, 943-947.	0.7	1



#	ARTICLE	IF	CITATIONS
450	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. The Cochrane Library, 2017, 12, CD011535.	1.5	164
451	Old and New Biological Therapies for Psoriasis. International Journal of Molecular Sciences, 2017, 18, 2297.	1.8	179
452	Novel carriers and approaches: insight for psoriasis management. , 2017, , 657-684.		1
453	Isoprenaline/ $\beta$ 2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis. BMC Cancer, 2017, 17, 875.	1.1	33
454	The Use of Apremilast to Treat Psoriasis During Deployment. Military Medicine, 2017, 182, 1628-1631.	0.4	3
455	Pathogenic Role of Cytokines and Effect of Their Inhibition in Psoriasis. , 0, , .		6
456	Guselkumab for the treatment of psoriasis. Expert Opinion on Biological Therapy, 2018, 18, 459-468.	1.4	33
457	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. Journal of the American Academy of Dermatology, 2018, 79, 277-286.e10.	0.6	163
458	Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. Current Medical Research and Opinion, 2018, 34, 1325-1333.	0.9	27
459	Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis. Molecular Pain, 2018, 14, 174480691876220.	1.0	12
460	Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. Journal of the American Academy of Dermatology, 2018, 79, 135-144.e7.	0.6	46
461	Patient preference study for different characteristics of systemic psoriasis treatments (Protimisis). Dermatologic Therapy, 2018, 31, e12592.	0.8	7
462	Indirubin: a novel topical agent in the treatment of psoriasis. British Journal of Dermatology, 2018, 178, 21-21.	1.4	9
463	Clinical Trial and Registry Data. Current Problems in Dermatology, 2018, 53, 15-27.	0.8	6
464	A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis. Clinical Drug Investigation, 2018, 38, 191-199.	1.1	36
465	Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology, 2018, 78, 383-394.	0.6	69
466	The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. Journal of Dermatological Treatment, 2018, 29, 557-568.	1.1	35
467	Immunogenicity of Biologic Agents in Psoriasis. , 2018, , 93-99.		0

#	ARTICLE	IF	CITATIONS
468	Tumor Necrosis Factor Inhibition. , 2018, , 111-121.		0
469	Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 2018, 154, 581.	2.0	74
470	Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. Dermatology and Therapy, 2018, 8, 173-194.	1.4	45
471	Drug survival of biologic treatments in psoriasis: a systematic review. Journal of Dermatological Treatment, 2018, 29, 460-466.	1.1	66
472	Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase 3 VOYAGE 1 and VOYAGE 2 studies. British Journal of Dermatology, 2018, 178, 132-139.	1.4	57
473	Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials. Value in Health, 2018, 21, 1-8.	0.1	18
474	Apremilast in psoriasis – a prospective real-world study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 254-259.	1.3	54
475	Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis. American Journal of Clinical Dermatology, 2018, 19, 209-222.	3.3	39
476	Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups. American Journal of Clinical Dermatology, 2018, 19, 405-423.	3.3	72
477	A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis. Journal of Dermatological Treatment, 2018, 29, 467-474.	1.1	6
478	The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis. Expert Review of Clinical Immunology, 2018, 14, 1-19.	1.3	25
479	Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials. British Journal of Dermatology, 2018, 178, 400-405.	1.4	6
480	Efeitos adversos do uso de imunobiológicos no tratamento da psoríase. , 2018, 97, 486-492.	0.0	0
481	Cost-effectiveness of apremilast in moderate to severe psoriasis in the United Kingdom. Cogent Medicine, 2018, 5, 1495593.	0.7	4
483	Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis. Experimental and Therapeutic Medicine, 2018, 16, 5085-5095.	0.8	16
484	Importance of assessing and adjusting for cross-study heterogeneity in network meta-analysis: a case study of psoriasis. Journal of Comparative Effectiveness Research, 2018, 7, 1037-1051.	0.6	29
485	Bimekizumab for the treatment of psoriatic disease. Expert Opinion on Biological Therapy, 2018, 18, 1193-1197.	1.4	16
486	Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. Journal of Immunology, 2018, 201, 1605-1613.	0.4	388

#	ARTICLE	IF	CITATIONS
487	Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. <i>BioDrugs</i> , 2018, 32, 193-199.	2.2	31
488	Biologics. Updates in Clinical Dermatology, 2018, , 73-92.	0.1	0
490	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018, 179, 615-622.	1.4	57
491	Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. <i>Journal of Dermatology</i> , 2018, 45, 1053-1062.	0.6	85
492	Biologics for the primary care physician: Review and treatment of psoriasis. <i>Disease-a-Month</i> , 2019, 65, 51-90.	0.4	62
493	Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. <i>PLoS ONE</i> , 2019, 14, e0220868.	1.1	118
494	Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis <sc>SOLAPSO</sc> â€“ Sociedad Latinoamericana de Psoriasis <i>(Latin American Psoriasis)</i> Tj ETQq0 0 0 rgBT /0 5 rlock 10 Tf 50 49	0.5	16
495	<p></p>Therapeutic drug monitoring of biologics in psoriasis</p>. <i>Biologics: Targets and Therapy</i> , 2019, Volume 13, 127-132.	3.0	20
496	Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children. <i>Children</i> , 2019, 6, 108.	0.6	31
497	Dimethyl fumarate is efficacious in severe plaque psoriasis. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 485-492.	1.0	6
498	Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease). <i>Seminars in Immunopathology</i> , 2019, 41, 633-644.	2.8	41
499	Risankizumab for the treatment of psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 851-857.	1.3	10
500	State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. <i>Current Opinion in Pharmacology</i> , 2019, 46, 90-99.	1.7	34
501	Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology. <i>Anais Brasileiros De Dermatologia</i> , 2019, 94, 76-107.	0.5	23
502	Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis. <i>International Immunopharmacology</i> , 2019, 73, 442-450.	1.7	20
503	<i>In vitro</i> human helper T-cell assay to screen antibody drug candidates for immunogenicity. <i>Journal of Immunotoxicology</i> , 2019, 16, 125-132.	0.9	13
504	Psoriasis in moderate grave plaque - immunobiological treatment. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2019, 65, 493-508.	0.3	1
505	Use of doseâ€“exposureâ€“response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2082-2086.	1.3	8

#	ARTICLE	IF	CITATIONS
506	Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1214-1223.	1.3	8
507	Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. <i>RMD Open</i> , 2019, 5, e000763.	1.8	27
508	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1029-1072.	0.6	542
509	Risankizumab in moderate-to-severe plaque psoriasis. <i>Immunotherapy</i> , 2019, 11, 1357-1370.	1.0	5
511	The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies. <i>PLoS ONE</i> , 2019, 14, e0225112.	1.1	18
512	Health Care Utilization and Cost Associated with Biologic Treatment Patterns Among Patients with Moderate to Severe Psoriasis: Analyses from a Large U.S. Claims Database. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 479-488.	0.5	39
513	Pharmacotherapeutic strategies for standard treatment-resistant psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 443-454.	0.9	14
514	Tildrakizumab for the treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 5-12.	1.3	19
515	Biologics and Psoriasis. <i>Dermatologic Clinics</i> , 2019, 37, 29-36.	1.0	43
516	Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 81-92.	0.3	18
517	Review of safety and efficacy of approved systemic psoriasis therapies. <i>International Journal of Dermatology</i> , 2019, 58, 649-658.	0.5	66
518	Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. <i>British Journal of Dermatology</i> , 2020, 182, 304-315.	1.4	33
519	US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , 2020, 31, 333-341.	1.1	23
520	Biologics for chronic inflammatory skin diseases: an update for the clinician. <i>Journal of Dermatological Treatment</i> , 2020, 31, 108-130.	1.1	17
522	Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals. <i>British Journal of Dermatology</i> , 2020, 182, 965-973.	1.4	26
523	Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 285-291.	0.5	61
524	Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses. <i>Dermatology and Therapy</i> , 2020, 10, 73-86.	1.4	38
525	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 1, CD011535.	1.5	86

#	ARTICLE	IF	CITATIONS
526	Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1138-1149.	0.6	37
527	Encuesta de opinión a pacientes con psoriasis moderada-grave sobre la persistencia de los tratamientos biológicos. <i>Actas Dermo-sifilográficas</i> , 2020, 111, 691-694.	0.2	2
528	Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis. <i>Rheumatology</i> , 2020, 59, 3657-3665.	0.9	2
529	Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. <i>Dermatology</i> , 2021, 237, 158-165.	0.9	3
530	Association of Pathogenic Th17 Cells with the Disease Severity and Its Potential Implication for Biological Treatment Selection in Psoriasis Patients. <i>Mediators of Inflammation</i> , 2020, 2020, 1-16.	1.4	12
531	Opinion Survey on Persistence of Biologic Therapies in Patients with Moderate to Severe Psoriasis. <i>Actas Dermo-sifilográficas</i> , 2020, 111, 691-694.	0.2	0
532	Pathophysiology, Clinical Presentation, and Treatment of Psoriasis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1945.	3.8	953
533	Biologics and small molecules in patients with scalp psoriasis: a systematic review. <i>Journal of Dermatological Treatment</i> , 2022, 33, 473-482.	1.1	6
534	Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 737-750.	0.6	3
535	Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups. <i>Systematic Reviews</i> , 2020, 9, 132.	2.5	14
536	Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 211-232.	1.3	12
537	Emerging systemic drugs in the treatment of plaque psoriasis. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 89-100.	1.0	23
538	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 431-447.	1.4	40
539	Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. <i>Journal of Dermatological Treatment</i> , 2020, 31, 470-475.	1.1	30
540	COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement. <i>Australasian Journal of Dermatology</i> , 2020, 61, 210-216.	0.4	43
541	Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 561-572.	0.6	5
542	Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration. <i>International Journal of Dermatology</i> , 2020, 59, 1043-1056.	0.5	19
543	Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , 2020, 32, 1-9.	1.1	1

#	ARTICLE	IF	CITATIONS
544	British Association of Dermatologists centenary year: standing on the shoulders of giants. <i>British Journal of Dermatology</i> , 2020, 182, 1-2.	1.4	16
545	Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. <i>Journal of Dermatological Treatment</i> , 2022, 33, 219-228.	1.1	17
546	Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times. <i>Dermatology and Therapy</i> , 2020, 10, 339-349.	1.4	37
547	Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 135-142.	1.3	29
548	Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review. <i>Dermatologic Therapy</i> , 2021, 34, e14498.	0.8	20
549	Tumor Necrosis Factor Inhibitors. , 2021, , 287-301.e7.		2
550	Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center. <i>Dermatologic Therapy</i> , 2021, 34, e14623.	0.8	12
551	Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , 2021, 32, 302-309.	1.1	11
552	The Role of Leptin in the Association between Obesity and Psoriasis. <i>Biomolecules and Therapeutics</i> , 2021, 29, 11-21.	1.1	26
553	Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values 1, 2, 3 or 5 derived from a statistical conversion method. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1161-1175.	1.3	13
554	Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. <i>Dermatology and Therapy</i> , 2021, 11, 885-905.	1.4	40
555	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD011535.	1.5	34
556	Biological anti-psoriatic therapy profoundly affects high-density lipoprotein function. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021, 1866, 158943.	1.2	4
557	Chronic Stress Activates PlexinA1/VEGFR2-JAK2-STAT3 in Vascular Endothelial Cells to Promote Angiogenesis. <i>Frontiers in Oncology</i> , 2021, 11, 709057.	1.3	7
558	The "cytokine storm": molecular mechanisms and therapeutic prospects. <i>Trends in Immunology</i> , 2021, 42, 681-705.	2.9	156
559	Potential Treatment of Psoriasis with Oral Spironolactone as TNF-Alpha Inhibitor " A Future Prospective Review. <i>Shanghai Ligong Daxue Xuebao/Journal of University of Shanghai for Science and Technology</i> , 2021, 23, 411-420.	0.1	0
560	Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 572-581.	0.6	36
561	Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2021, 11, 1965-1998.	1.4	14

#	ARTICLE	IF	CITATIONS
562	New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. Journal of Investigative Dermatology, 2021, 141, 2328-2337.	0.3	21
564	Comparison of Biologics and Oral Treatments for Plaque Psoriasis. JAMA Dermatology, 2020, 156, 258.	2.0	169
566	Targeted Therapies and Biomarkers for Personalized Treatment of Psoriasis. , 2015, , 77-100.		2
567	Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2012, 22, 532-540.	0.9	19
568	Management of Psoriatic Arthritis. , 2007, , 97-113.		1
570	ETANERCEPT REDUCES ACUTE TISSUE INJURY AND MORTALITY ASSOCIATED TO ZYMOSAN-INDUCED MULTIPLE ORGAN DYSFUNCTION SYNDROME. Shock, 2008, 29, 560-571.	1.0	5
571	Casual or Causal? Two Unique Cases of Hodgkin's Lymphoma: A Case Report and Literature Review. American Journal of Case Reports, 2017, 18, 553-557.	0.3	4
572	The safety of etanercept for the treatment of plaque psoriasis. Therapeutics and Clinical Risk Management, 2007, 3, 245-258.	0.9	18
573	A Mechanism-Based Classification of Dermatologic Reactions to Biologic Agents Used in the Treatment of Cutaneous Disease: Part 2. Dermatitis, 2009, 20, 243-256.	0.8	13
574	Psoriasis and Treatment: Past, Present and Future Aspects. Acta Dermato-Venereologica, 2020, 100, 70-80.	0.6	77
575	Infliximab for the treatment of adults with psoriasis. Health Technology Assessment, 2009, 13, 55-60.	1.3	7
576	Infliximab for the treatment of adults with psoriasis. Health Technology Assessment, 2009, 13, 55-60.	1.3	42
577	Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. Health Technology Assessment, 2017, 21, 1-244.	1.3	16
578	Biological therapy of psoriasis. Indian Journal of Dermatology, 2010, 55, 161.	0.1	36
579	Autoimmunphänomene unter Therapie mit Biologics. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2007, , 52-57.	0.0	0
580	Biologika bei Psoriasis vulgaris. Pharma-Kritik (discontinued), 2007, 28, .	0.0	1
581	Biologic Therapies For Psoriasis. , 2009, , .		0
584	NORMAS DE BOA PRÁTICA PARA O TRATAMENTO DA PSORÍASE EM PLACAS EM IDADE NÃO PEDIÁTRICA COM BIOLÓGICOS. Journal of the Portuguese Society of Dermatology and Venereology, 2011, 69, 532.	0.0	2

#	ARTICLE	IF	CITATIONS
585	Biotech on the Rise: The Treatment of Psoriasis with Biological Drugs. , 0, , .		0
586	Biologic Therapies. , 2013, , 357-383.		0
588	Biological Treatment of Psoriasis. Clinical Medicine Insights Dermatology, 0, , 19.	0.0	0
591	Biologics in the Treatment of Plaque Psoriasis: Drug Selection by Means of the SOJA Method. Journal of Pharmaceutical Care & Health Systems, 2016, 1, .	0.1	0
592	43-Year-Old with Recurrence of Red, Scaly Rash. , 2017, , 95-103.		0
593	Biologic Therapies for Psoriasis. , 2017, , 757-765.		0
594	Comparative Clinical Studies for Biosimilars as Part of a Stepwise Approach. AAPS Advances in the Pharmaceutical Sciences Series, 2018, , 471-487.	0.2	0
595	Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multipleâ€treatments metaâ€analysis. JDDG - Journal of the German Society of Dermatology, 2021, 19, 47-56.	0.4	12
596	Systemic Drugs Used inâ€Dermatology. , 2020, , 177-212.		0
597	How current biologic therapies affect the risk of major adverse cardiovascular events in patients with plaque psoriasis? A systematic review and meta-analysis of randomized controlled trials. Postepy Dermatologii i Alergologii, 2020, 37, 986-994.	0.4	2
598	Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis. Frontiers in Pharmacology, 2021, 12, 774808.	1.6	16
599	Realâ€world, longâ€term treatment patterns of commonly used biologics in Canadian patients with moderateâ€toâ€severe chronic plaque psoriasis. Journal of Dermatology, 2022, 49, 95-105.	0.6	11
600	Biologic therapy for psoriasis: an overview of infliximab, etanercept, adalimumab, efalizumab, and alefacept. , 2008, , 141-158.		0
603	Treatment of Psoriasis. , 2008, , 99-113.		0
605	Biological treatments for psoriasis. Therapy: Open Access in Clinical Medicine, 2006, 3, 425-436.	0.2	0
606	Biologics in Psoriasis. , 2007, , 81-96.		0
608	Evolution of immunotherapy methods for psoriasis and psoriatic arthritis: from total immunosuppression to selective treatment of therapeutic targets. Medical Alphabet, 2020, , 15-21.	0.0	0
610	Immunomodulators in the Treatment of Psoriasis. Journal of Drug Delivery and Therapeutics, 2020, 10, 213-215.	0.2	0



#	ARTICLE	IF	CITATIONS
611	Systemic treatment of psoriasis: from methotrexate to biologics. <i>Vestnik Dermatologii I Venerologii</i> , 2020, 96, 7-26.	0.2	6
612	Biological markers in the etiology of psoriasis: Targeted treatment options. <i>Biologics: Targets and Therapy</i> , 2007, 1, 11-8.	3.0	2
613	Psoriasis (chronic plaque). <i>Clinical Evidence</i> , 2009, 2009, .	0.2	1
614	Etanercept in psoriasis: the evidence of its therapeutic impact. <i>Core Evidence</i> , 2007, 2, 51-62.	4.7	3
615	Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2014, 7, 16-24.	0.1	24
616	Targeting TNF $\alpha$ in severe psoriasis-mass spectrometry reveals a time-dependent specific inhibition of Factor H in responding patients. <i>American Journal of Translational Research (discontinued)</i> , 2018, 10, 4338-4349.	0.0	0
617	Development of A Blockchain Framework for Virtual Clinical Trials. <i>AMIA ... Annual Symposium proceedings</i> , 2020, 2020, 1412-1420.	0.2	0
618	Plaque-type psoriasis inhibitors. <i>International Immunopharmacology</i> , 2021, 101, 108326.	1.7	6
619	IL-23 blockers in dermatology. <i>Indian Journal of Drugs in Dermatology</i> , 2021, 7, 51.	0.0	0
620	Update on the etiopathogenesis of psoriasis (Review). <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 201.	0.8	22
622	Immune mechanisms of psoriasis. New strategies of biotherapy. <i>Vestnik Dermatologii I Venerologii</i> , 2010, 86, 35-47.	0.2	11
623	Pharmacoeconomic aspects of treatment of psoriasis with biological drugs. <i>Vestnik Dermatologii I Venerologii</i> , 2012, 88, 26-31.	0.2	1
624	Drug survival of biologic agents in patients with psoriatic arthritis from a medical center in southern Taiwan. <i>Dermatologica Sinica</i> , 2022, 40, 20.	0.2	4
626	Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis. <i>Advances in Therapy</i> , 2022, 39, 2256-2269.	1.3	10
627	Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis. <i>Pharmaceutics</i> , 2022, 14, 654.	2.0	9
628	Biosimilar versus originator etanercept: a real-life clinical study. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, .	0.1	2
629	The Relapse of Psoriasis: Mechanisms and Mysteries. <i>JID Innovations</i> , 2022, 2, 100116.	1.2	37
630	Emerging Treatment Regimens in Psoriasis: Are There Advantages Over Current Biologic Therapies?. <i>EMJ Dermatology</i> , 0, , 106-121.	0.0	1

#	ARTICLE	IF	CITATIONS
631	The Role of Helper T Cells in Psoriasis. <i>Frontiers in Immunology</i> , 2021, 12, 788940.	2.2	70
632	De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review. <i>Biomedicines</i> , 2022, 10, 1034.	1.4	4
633	Inhibitors of tumor necrosis factor-alpha for treatment of psoriatic patients. <i>Vestnik Dermatologii i Venerologii</i> , 2010, 86, 7-15.	0.2	1
634	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	25
635	Association Between Short-Term PASI90 Achievement and Drug Survival of Biologics in Patients with Psoriasis. <i>Annals of Dermatology</i> , 2022, 34, 173.	0.3	2
636	Risk of respiratory tract infections and serious infections in psoriasis patients treated with biologics: Results from the BioCAPTURE registry. , 0, , .		1
637	Infection risk in psoriatic patients receiving tumour necrosis factor inhibitors: a 20-year systematic review and meta-analysis of randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2301-2315.	1.3	1
638	Risk of Candida Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-11.	0.8	5
639	Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
640	Pathogenesis, multi-omics research, and clinical treatment of psoriasis. <i>Journal of Autoimmunity</i> , 2022, 133, 102916.	3.0	21
642	Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis. <i>Current Opinion in Pharmacology</i> , 2022, 67, 102292.	1.7	4
643	Will Biosimilars Change the Treatment Paradigm in Psoriasis?. <i>EMJ Dermatology</i> , 0, , 39-46.	0.0	0
644	Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis. <i>Life</i> , 2022, 12, 2075.	1.1	1
645	Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches. <i>Drug Discovery Today</i> , 2023, 28, 103465.	3.2	11
646	The Evolving Landscape of Rheumatology: Biosimilarity and Extrapolation. <i>European Medical Journal Rheumatology</i> , 0, , 2-9.	0.0	0
647	ANALYSIS OF THE EFFICACY AND SAFETY OF GENETICALLY ENGINEERED BIOLOGICAL THERAPY FOR MODERATELY SEVERE AND SEVERE FORMS OF PSORIASIS. , 2022, 19, 3-9.		0
648	Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: A systematic review and aggregate data meta-analysis of randomized controlled trials. <i>International Journal of Rheumatic Diseases</i> , 2023, 26, 625-637.	0.9	4
649	Interleukin-17 and Tumor Necrosis Factor Show a Functional Hierarchy to Regulate the Production of Matrix Metalloproteases by Monocytes from Patients with Psoriasis. <i>Journal of Interferon and Cytokine Research</i> , 2023, 43, 140-146.	0.5	0

#	ARTICLE	IF	CITATIONS
650	Systematic review and estimated costâ€efficacy of biologics compared with narrowband ultraviolet B light for the treatment of moderate to severe psoriasis and atopic dermatitis. International Journal of Dermatology, 2023, 62, 986-999.	0.5	3
655	Biologic Agents for Psoriasis. , 2023, , 1595-1606.		0